Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Undecane SCHEMBL27865572 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Octane SCHEMBL8554735 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Decane SCHEMBL28102289 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Nonane SCHEMBL27865569 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Undecane SCHEMBL28453375 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Heptane SCHEMBL28681950 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Octane SCHEMBL27625 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Heptane SCHEMBL28458543 | 1.00 | TSHR (0.67) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Octane SCHEMBL29415664 | 0.96 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA | |
| Decane SCHEMBL7073253 | 0.96 | TSHR (0.61) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022000868-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海皓元生物医药科技有限公司 | 2022-01-06 | — | — | WO | claimed |
| EP-2122418-B1 | STRIPPER FOR COATING LAYER | AZ ELECTRONIC MATERIALS USA (US) | 2012-08-08 | — | — | EP | claimed |
| US-8026201-B2 | Comprising: a fluoride source, an organic quaternary ammonium base, and a solvent selected from an organic solvent, water, and mixtures thereof; for removing silicon-based anti-reflective coatings/hardmask layers from microelectronics; etch selectivity | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2011-09-27 | — | — | US | claimed |
| EP-2122418-A2 | STRIPPER FOR COATING LAYER | AZ Electronic Materials USA Corp. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008081416-A2 | STRIPPER FOR COATING LAYER | AZ ELECTRONIC MATERIALS USA CORP. (DE) | 2008-07-10 | — | — | WO | claimed |
| EP-4622987-A1 | NEGATIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Sage Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025039676-A1 | PAN-KRAS PROTEIN TARGETED DEGRADER COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2025-02-27 | — | — | WO | disclosed |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| EP-4442683-A1 | AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Kygent Pharmaceutical Co., Ltd (CN) | 2024-10-09 | — | — | EP | disclosed |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024120424-A1 | COMPOUND TARGETING PAN-KRAS PROTEIN DEGRADATION AGENT AND USE THEREOF | 贝达药业股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| WO-2024112759-A1 | NEGATIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-04 | — | — | US | disclosed |
| WO-2001062233-A2 | ADENOSINE RECEPTOR MODULATORS | F. HOFFMANN LA ROCHE AG (CH) | 2001-08-30 | — | — | WO | disclosed |
| US-5892035-A | FLUORINATING THE CORRESPONDING DIAZABICYCLOALKALINE COMPOUND | DAIKIN INDUSTRIES LTD. (JP) | 1999-04-06 | — | — | US | disclosed |
| US-5892106-A | Preparation of 3-fluoro oxindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-04-06 | — | — | US | disclosed |
| US-5808095-A | Preparation of 3-fluoro oxindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5780465-A | 4-substituted 5-polycyclylpyrimidine herbicides | DOW AGROSCIENCES LLC (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0842177-A1 | PROCESS FOR THE MANUFACTURE OF 1-SUBSTITUTED-4-FLUORO-1,4-DIAZONIABICYCLO[2.2.2]OCTANE SALTS | AlliedSignal Inc. (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997042193-A1 | PROCESS FOR THE MANUFACTURE OF 1-SUBSTITUTED-4-FLUORO-1,4-DIAZONIABICYCLO[2.2.2]OCTANE SALTS | ALLIEDSIGNAL INC. (US) | 1997-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027196-A1 | Adenosine receptor ligands and their use in the treatment of disease | ADORA2A, ADORA2B, ADORA1 | TSHR 435/4885THRB 607/4885DNM1 1963/4885 |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | RIPK1, RIPK3, RIPK4 | TSHR 3513/4885THRB 2181/4885DNM1 814/4885 |
| US-20240208986-A1 | PHENYL AZEPINES AS RIPK1 INHIBITORS AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | TSHR 4432/4885THRB 4089/4885DNM1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.